704 results about "Phosphatidylcholine" patented technology

Formulations or delivery systems are provided for controlled release of therapeutically active agents. The delivery systems are composed of polymer and lipid materials and may be prepared as a gel, paste, solution, film, implant or barrier depending on the intended application. The polymer component of the matrix is the naturally occurring biomaterial, chitosan, or a mixture of chitin and chitosan. The lipid component may include phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidyl or a mixture thereof. The delivery system may be used for delivery of hydrophilic agents, hydrophobic agents or combinations thereof. The therapeutically active agents may be formulated within the matrix as free agents or incorporated into particles. In a preferred embodiment the agents are incorporated into polymeric particles that are dispersed throughout the matrix.

A topical skin rejuvenation preparation to relieve wrinkles, increase the skin's natural production of hyaluronic acid, reverse the lack of suppleness, hydrate from within, erase spider veins, reduce varicose veins, lighten aging dark blotches (“liver spots”/Lentigos, Senile Lentigines), decrease acne, and reduce under eye puffiness includes Glucosamine (2-amino-2-deoxy-alpha-D-glucose), a hexosamine (6 carbon amino sugar), including its derivative and precursor compounds: Glucosamine Sulfate, Glucosamine Hydrochloride, Glucose-6-Phosphate, Acetyl Glucosamine, Fructose-6-phosphate, Glucosamine-6-Phosphate, to increase production of Hyaluronic acid and collagen from Glucosamine Sulfate, its precursors and derivatives and to increase skin muscle tone by Dimethylaminoethanol (DMAE) while over coming deficiency it creates in each cell's production of PhosphatidylCholine, whose deficiency damages cell membranes, as well as mitochondrial and lysosome membranes.

A method of formulating insulin compositions comprises preparing a carrier having a phosphatidylcholine component which entraps insulin, stabilizing insulin compositions at room temperatures.

The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.

The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin. The present invention further relates to the topical application to the skin of such compositions, and/or preparations containing them, for the prevention and/or treatment of damage to skin.

Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long/short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.

The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

A disposable cartridge is disclosed for use with an electronic device for producing an aerosol for inhalation by a person. The cartridge comprises a liquid container containing a liquid which when aerosolized is intended for inhalation by a person; and a transducer that, when actuated, causes the liquid from the container to be aerosolized such that the aerosol may be inhaled by a person. In various embodiments, the liquid comprises: a liposomal carrier; a liquid mixture having an active agent entrapped by liposomes; and a liquid mixture comprising a nanodispersion. The liquid may include nicotine, tetrahydrocannabinol, cannabidiol, or nanoparticles formed by an oil droplet covered by a monolayer of phosphatidylcholine. The transducer preferably comprises a mesh material with the transducer and the mesh material forming a piezo mesh disk for aerosolizing the liquid.

The present invention relates to viscous injectable phosphatidylcholine preparations and their use for the reduction or removal of localized adipose tissue (fat) deposits, and to intra-fat pad injection and implant methods of administering such preparations for the non-surgical removal or reduction of localized fatty deposits.

The extraction process of phosphatidylcholine from soybean phosphatide includes multistage countercurrent extraction of soybean phosphatide with double-liquid phase mixed solvent comprising saturated alkane, acetonitrile and low carbon alcohol and the vacuum exsolution of ultimate extracted liquid to obtain the product with phosphatidylcholine content over 80 % in the yield over 80 %. The said technological process is simple, less investment in the apparatus, and suitable for continuous and automatic industrial production.

The invention discloses a dietetic food composition for losing weight. The composition comprises the following ingredients: fresh meat and aquatic product, vegetables, fruits, dried mushroom products, cereals, beans, nut meat, edible vegetable oil, eggs, protein hydrolysate powder, dietary fiber powder, konjac powder, guar gum, polyols, phosphatidylcholine, fruit polyphenols, L-carnitine, vitamin A, vitamin E, vitamin C, thiamine hydrochloride, riboflavin, nicotinamide, pyridoxine hydrochloride, folic acid, cyanide-containing cobalt and pantothenic acid. By adopting the dietetic food composition disclosed by the invention, the total energy intake is reduced under the premise of ensuring normal basic metabolic rate, the requirements of the body on protein at a low-energy diet period are improved, and related nutrients are replenished to facilitate body fat, visceral fat and blood lipid metabolism, so as to achieve the target of losing weight. Meanwhile, the invention also discloses a preparation method of the dietetic food composition and use of the dietetic food composition in preparation of a medicament for preventing or treating an obesity disease.

A process for extracting phosphatidylcholine from the powdered soybean phosphatide incldues multi-stage counter-current extracting with the mixed solvent of acetonitrile and low-carbon alcohol, and vacuum removing of solvent. Its advantages are high purity (more than 70%), and high output rate (more than 70%).

The invention relates to a method for preparing phosphatidylserine and phosphatidylcholine, and belongs to the field of food health-care products. The method comprises the following steps of: extracting soybean meal phospholipid which is used as a raw material by an organic solvent, and then distilling and drying to respectively obtain a phosphatidylcholine crude product and a phosphatidylserine crude product; and separating and purifying the phosphatidylcholine crude product and the phosphatidylserine crude product through a silica gel column of 200-300 meshes, eluting with a mixed organic solvent, concentrating the eluant, and drying to obtain phosphatidylserine and phosphatidylcholine. According to the method, the purities of the phosphatidylserine and the phosphatidylcholine meet requirements of new resource foods, so that the phosphatidylserine and the phosphatidylcholine can be used as new resource dietary supplements and have high economic added values; and the phosphatidylserine and the phosphatidylcholine are prepared at the same time by effectively combining simple extraction of the phosphatidylserine and the simple extraction of the phosphatidylcholine. By the method, the production time is shortened, the production cost is reduced, the production rate is improved, the operation is simple, and the products have safety.

The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-70 mol % of a phosphatidylcholine lipid, 25-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and oxaliplatin. Oxaliplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the oxaliplatin weight is from about 20:1 to about 65:1. Methods for the preparation of liposomal oxaliplatin and the treatment of cancer are also disclosed.

The invention discloses a liposome preparation of sodium aspirin and sodium pravastatin. The liposome is mainly prepared from the following components in part by weight: 20 to 40 parts of sodium aspirin, 81 parts of sodium pravastatin, 200 to 1,000 parts of hydrogenated soybean phosphatidylcholine, 50 to 500 parts of cholesterol and 100 to 400 parts of poloxamer 188. The invention also discloses a solid preparation of a sodium aspirin and sodium pravastatin medicinal composition, which is prepared from the liposome preparation of sodium aspirin and sodium pravastatin, and other excipients usually used pharmaceutically. The quality of the preparation is improved and the toxic and side effects are reduced.

The invention discloses pharmaneutical compositions comprising a phospholipid formulation that is fluidized with an oil composition containing a pre-determined ratio of omega 6 and omega 3 fatty acids. In particular the invention discloses phosphatidylcholine compositions that are fluidized with a pre-determined ratio of linoleic acid and alpha linolenic acid.

A process for preparing the high-purity phosphatidylcholine from vegetative phosphatide includes extracting, separating alcohol-soluble components, vacuum centrifugal concentrating, adding it to chromatographic Al2O3 column, eluting with the mixture of water and low-carbon alcohol, vacuum concentrating and drying. Its advantages are high purity and quality, high output rate and no poison and pollution.

The invention discloses a special diluent for swine mycoplasmal pneumonia vaccines. The special diluent mainly contains a recombinant P97R1 protein immunostimulating complex (ISCOM-P97R1); and in addition, the special diluent also possibly contains other water-based adjuvants comprising levomisole, astragalus polysaccharide or/and carbomer. 1 ml of diluent solution contains 0.1-1 mg of QuilA, 0.02-0.2 mg of cholesterol, 0.02-0.2 mg of phosphatidylcholine and 0.4-4 mg of P97R1 antigen; and in addition, 1 ml of diluent solution also possibly contains 2-20 mg of levomisole, 20-100 mg of astragalus polysaccharide or/and 3-10 mg of carbomer and a phosphate buffer solution for the rest. The diluent is specially used for dissolving or diluting the swine mycoplasmal pneumonia vaccines comprising a live vaccine and an inactivated vaccine, has the double effects of complementing vaccine antigen protection spectrums and improving the vaccine cell and humoral immunostimulation capability, can remarkably improve the toxic attack protection efficacy of the vaccines, and also has the advantages of being simple and convenient to operate, good in syringeability and free from remarkable toxic side reaction due to the adoption of a hydrosolvent system at the same time.

The invention discloses a metabonomics-based diagnosis marker for chronic obstructive pulmonary disease and application thereof. The diagnosis marker comprises the following 28 blood plasma metabolismmarkers: phosphatidylcholine PC 16:1-36:3, phosphatidylcholine PC 26:0-22:4, phosphatidylcholine PC 26:0-22:3, phosphatidylcholine PC 47:5e, phosphatidylcholine PC 44:11e, phosphatidylcholine PC 16:0-24:5, phosphatidylcholine PC 20:2-20:3, phosphatidylcholine PC 40:10, phosphatidylcholine PC 38:9e, phosphatidylcholine PC 18:1-20:4, phosphatidylcholine PC 16:0-20:3, phenylacetaldehyde, dihydrouracil, nicotinamide, 4-methoxycinnamic acid, ketovaline, threonine, DL-3-aminoisobutyric acid, pyruvic acid, stachyose, caffeic acid, N, N-dimethylaniline, maltotriose, D(-)-gulonate-gamma-lactone, and L-asparaginase. The marker provided by the invention has good classification on metabolome data of patients suffering chronic obstructive pulmonary disease and healthy people, and can accurately distinguish the patients suffering chronic obstructive pulmonary disease from the healthy people.

The invention provides an extraction process of phosphatidylcholine with antarctic krill as a source. The extraction process comprises the following steps: collecting heads of the antarctic krill, adding water for decoction, stirring, sending the krill head decoction liquid to a cold pressing machine for solid-liquid separation, to obtain an oily liquid rich in phospholipid and krill heads and other solids; adding absolute ethyl alcohol into the krill heads and other solids, carrying out high shearing extraction, carrying out centrifugal separation, and concentrating to obtain an oily liquid; merging the oily liquids, drying under a reduced pressure, then filtering through a plate frame filter to remove insoluble substances, followed by carrying out membrane separation and concentration, carrying out column chromatography separation and purification, carrying out freeze drying, and thus obtaining the phosphatidylcholine product. The invention also provides a preparation method for phosphatidylserine with the antarctic krill as the source. The preparation method comprises the steps of hydrolyzing the extracted phosphatidylcholine by phospholipase D, and extracting to obtain phosphatidylserine rich in DHA and EPA. The extraction process and the preparation method are environmentally friendly, and are low in cost; and the obtained products have high content and good activity, and can be industrially produced.